Drug development for alzheimer's neuroinflammation
Active Cooperative Agreement Awarded Last action
- Award ID
- U01AG094622
- Recipient
-
University Of Southern California UEI G88KLJR3KYT5
- Awarding agency
-
National Institute on Aging
National Institutes of Health, Department of Health and Human Services
- Obligated
- $3,152,398
Award facts
- Assistance listing
- 93.866 Aging Research
- Completion date 25% complete
- Place of performance
- Los Angeles, CA 90089, USA
Award details come from USAspending.gov.
Description
- Abstract
- Alzheimer's disease (ad) affects around 6 million americans and imposes a burden of $320 billion on the US economy. Since 2003, very few medications have been approved for ad. Neuroinflammation is one of the leading mechanisms for ad pathology affecting several brain cell types and is an active target for treatment. One of the promising targets for neuroinflammation is the calcium-dependent phospholipase A2 (CPLA2) which regulates neuronal membrane excitability, polyunsaturated fatty acid metabolism, and vascular integrity. Increased activation of CPLA2 in the brain is associated with eicosanoid inflammatory lipid profiles and is observed in ad, post-stroke, parkinson, spinal cord injury, and traumatic brain animal models. Importantly, genetic or pharmacological reduction of CPLA2 activity ameliorates disease severity across these models. Our group has demonstrated that carrying the apoe E4 (APOE4) allele, the strongest genetic risk factor for ad, activates CPLA2 in the brain. In postmortem human brain tissues, we reported eicosanoid lipid activation profiles consistent with CPLA2 activation in APOE4 ad. Despite the strong preclinical signals, no brain penetrant CPLA2 inhibitors advanced to clinical trials. Our team has established a structure-based drug discovery platform and used IT to identify new lead compounds that inhibit CPLA2, confirming their potency in vitro and in cells and brain penetrance. Our current lead has an affinity, safety, and blood- brain barrier penetration consistent with drug-like properties and initial SAR suggesting high optimization potential. Moreover, we developed a brain imaging tool based on the uptake of arachidonic acid in the brain to assess the efficacy of CPLA2 inhibition in vivo. Using these platforms, we plan to establish a comprehensive SAR for our main and backup lead series and develop a screening funnel. In close collaboration with consultants and contractors, this screening funnel will then be employed to optimize the lead potency, selectivity, admet, and PK properties relevant for CPLA2 inhibitors, including in vivo potency and minimal toxicity profiles. This would allow for the selection of clinical candidates for the development of IND- enabling studies and preparation of IND targeting ad neuroinflammation.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $1,672,123 | |
| Original award | $1,480,275 |
Quick answers
Who received award U01AG094622?
U01AG094622 was awarded to University Of Southern California by National Institute on Aging (National Institutes of Health) on August 1, 2025.
How much is award U01AG094622 worth?
$3,152,398 has been obligated on U01AG094622.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award